Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

Nicholas C Turner, Erica L Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Adam M Brufsky, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Nuri Karadurmus, Einav Gal-Yam, Wei-Pang Chung, Seock-Ah Im, Alberto Zambelli, Florence Dalenc, Mafalda Oliveira, Hiroshi Ishiguro, Chiun-Sheng Huang, Teresa Klinowska, Steven Fox, Christopher Morrow, Lídia Robert, Cynthia Huang-Bartlett, François-Clément Bidard

Open source

DOI: 10.1016/s1470-2045(26)00287-1
Published: 2026-08
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00287-1,
  title = {Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial},
  author = {Nicholas C Turner and Erica L Mayer and Yeon Hee Park and Wolfgang Janni and Cynthia Ma and Massimo Cristofanilli and Giampaolo Bianchini and Kevin Kalinsky and Hiroji Iwata and Stephen Chia and Adam M Brufsky and Peter A Fasching and Zbigniew Nowecki and Javier Pascual and Nuri Karadurmus and Einav Gal-Yam and Wei-Pang Chung and Seock-Ah Im and Alberto Zambelli and Florence Dalenc and Mafalda Oliveira and Hiroshi Ishiguro and Chiun-Sheng Huang and Teresa Klinowska and Steven Fox and Christopher Morrow and Lídia Robert and Cynthia Huang-Bartlett and François-Clément Bidard},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(26)00287-1},
  url = {https://doi.org/10.1016/s1470-2045(26)00287-1}
}

RIS

TY  - JOUR
TI  - Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
AU  - Nicholas C Turner
AU  - Erica L Mayer
AU  - Yeon Hee Park
AU  - Wolfgang Janni
AU  - Cynthia Ma
AU  - Massimo Cristofanilli
AU  - Giampaolo Bianchini
AU  - Kevin Kalinsky
AU  - Hiroji Iwata
AU  - Stephen Chia
AU  - Adam M Brufsky
AU  - Peter A Fasching
AU  - Zbigniew Nowecki
AU  - Javier Pascual
AU  - Nuri Karadurmus
AU  - Einav Gal-Yam
AU  - Wei-Pang Chung
AU  - Seock-Ah Im
AU  - Alberto Zambelli
AU  - Florence Dalenc
AU  - Mafalda Oliveira
AU  - Hiroshi Ishiguro
AU  - Chiun-Sheng Huang
AU  - Teresa Klinowska
AU  - Steven Fox
AU  - Christopher Morrow
AU  - Lídia Robert
AU  - Cynthia Huang-Bartlett
AU  - François-Clément Bidard
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(26)00287-1
UR  - https://doi.org/10.1016/s1470-2045(26)00287-1
ER  -

APA

Turner, N. C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C., Cristofanilli, M., Bianchini, G., Kalinsky, K., Iwata, H., Chia, S., Brufsky, A. M., Fasching, P. A., Nowecki, Z., Pascual, J., Karadurmus, N., Gal-Yam, E., Chung, W., Im, S., Zambelli, A., Dalenc, F., Oliveira, M., Ishiguro, H., Huang, C., Klinowska, T., Fox, S., Morrow, C., Robert, L., Huang-Bartlett, C., & Bidard, F. (2026). Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00287-1

Source records

crossref · retrieved 2026-09-26T05:16:23.720Z